Lithium Benzoate Cocrystals for Controlled Release and Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The challenge in producing pharmaceutical co-crystals of lithium benzoate lies in identifying suitable co-formers and ratios, as well as methods for making such co-crystals, which are typically done through trial and error, and there is a need for co-crystals with improved properties like bioavailability and hygroscopicity.
Innovation Solution
The development of co-crystals of lithium benzoate with specific co-formers (e.g., sorbic acid, trans-cinnamic acid, and nicotinic acid) in defined molecular ratios, along with methods for their preparation, including mixing and heating processes to form desirable co-crystals.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If conventional lithium salts (lithium hydroxide, lithium carbonate, lithium chloride) are used, then they are commercially available and easy to manufacture, but they have high solubility in water causing rapid release and short duration of action
Solution Approach 1:
The patent creates a composite material by forming a cocrystal between lithium benzoate and a coformer (such as mandelic acid, phenylglycine, or phenylalanine). This composite structure allows the lithium salt to maintain its therapeutic benefits while reducing water solubility through the formation of a less soluble cocrystal lattice, thereby extending duration of action without sacrificing manufacturability
Solution Approach 2:
The patent changes the physical and chemical parameters of the lithium salt by selecting specific coformers with different molecular structures and properties. By varying the coformer (e.g., mandelic acid, phenylglycine, phenylalanine), the patent optimizes the cocrystal's solubility, stability, and duration of action parameters while maintaining ease of manufacture through conventional cocrystal formation techniques
2Duration of action of moving object
If lithium salts with low solubility are used to extend duration of action, then duration is improved, but bioavailability and rate of release are reduced
Solution Approach 1:
The patent optimizes the balance between solubility and duration by carefully selecting coformers and adjusting the molar ratio in the cocrystal. This parameter optimization ensures that the cocrystal releases lithium at a controlled rate that maintains therapeutic levels over time while preserving adequate bioavailability, achieving both extended duration and sufficient quantity of substance delivery
3Duration of action of moving object
If lithium benzoate cocrystals are designed for controlled release, then duration of action is extended, but the complexity of crystal structure design increases
Solution Approach 1:
The patent employs self-assembly principles where lithium benzoate and the coformer spontaneously form a cocrystal structure through molecular recognition and self-organization. This self-service approach to crystal formation simplifies the design process by relying on the inherent molecular properties of the components rather than requiring complex external structural design, thereby achieving controlled release with reduced design complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The resulting co-crystals exhibit improved properties such as bioavailability and hygroscopicity, making them suitable for treating neuropsychiatric disorders.
Implementation Method 1
the cocrystals of Formula I have a solubility in water that is lower than the solubility of lithium benzoate in water... the cocrystals of Formula I find use in the preparation of a pharmaceutical composition for the treatment of a mood disorder
Implementation Method 2
Lithium benzoate cocrystals having the formula I... wherein A and B independently represent H or D, or a mixture thereof
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present disclosure provides co-crystals of a lithium benzoatecompound and a co-former compound of Formula (I). Also provided herein are methods of preparing the co-crystals and uses thereof in treating and/or reducing the risk for a neuropsychiatric disorder (e.g., schizophrenia, psychotic disorders, depressive disorders, bipolar disorders, or neurodegenerative disorders).